443 related articles for article (PubMed ID: 27860104)
1. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
Hoffmann C; Welz T; Sabranski M; Kolb M; Wolf E; Stellbrink HJ; Wyen C
HIV Med; 2017 Jan; 18(1):56-63. PubMed ID: 27860104
[TBL] [Abstract][Full Text] [Related]
2. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors.
Hoffmann C; Llibre JM
AIDS Rev; 2019; 21(1):4-10. PubMed ID: 30899113
[TBL] [Abstract][Full Text] [Related]
5. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
[TBL] [Abstract][Full Text] [Related]
7. Adverse events of raltegravir and dolutegravir.
Elzi L; Erb S; Furrer H; Cavassini M; Calmy A; Vernazza P; Günthard H; Bernasconi E; Battegay M;
AIDS; 2017 Aug; 31(13):1853-1858. PubMed ID: 28692533
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
[TBL] [Abstract][Full Text] [Related]
10. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
Osterholzer DA; Goldman M
Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
Rolle CP; Castano J; Nguyen V; Patel K; Hinestrosa F; DeJesus E
Antivir Ther; 2023 Feb; 28(2):13596535231163703. PubMed ID: 36896821
[TBL] [Abstract][Full Text] [Related]
13. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
14. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect.
Yombi JC
AIDS Rev; 2018; 20(1):14-26. PubMed ID: 29628511
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
[TBL] [Abstract][Full Text] [Related]
17. Might dolutegravir be part of a functional cure for HIV?
Wainberg MA; Han YS; Mesplède T
Can J Microbiol; 2016 May; 62(5):375-82. PubMed ID: 27031127
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
Kandel CE; Walmsley SL
Drug Des Devel Ther; 2015; 9():3547-55. PubMed ID: 26185421
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]